ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu, Lihui; Ghose, Arup K; Quail, Matthew R; Albom, Mark S; Durkin, John T; Holskin, Beverly P; Angeles, Thelma S; Meyer, Sheryl L; Ruggeri, Bruce A; Cheng, Mangeng.
; 48(16): 3600-9, 2009 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-19249873
ALCL: is it now a curable disease?
Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC.
Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer.
Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma.
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
Anaplastic large cell lymphoma with TP63 rearrangement: A dismal prognosis.
Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Structural basis for the recognition of c-Src by its inactivator Csk.